Recent Quotes
My Watchlist
Indicators
Local Stocks
NewsOK Local Stocks
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Autolus Therapeutics Plc ADR (NQ: AUTL )

4.240 +0.050 (+1.19%)
Streaming Delayed Price Updated: 11:37 AM EDT, Jun 5, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 168,204
Open 4.160
Bid (Size) 4.240 (2)
Ask (Size) 4.250 (4)
Prev. Close 4.190
Today's Range 4.160 - 4.350
52wk Range 2.010 - 7.450
Shares Outstanding 52,346,231
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Autolus Therapeutics presents longer-term follow-up and additional data analysis of Pivotal Phase 2 FELIX study of obe-cel for adult r/r B-ALL in an oral presentation at ASCO
From Autolus Therapeutics plc
Via GlobeNewswire
Crude Oil Gains 1%; GameStop Shares Plunge
Via Benzinga
Exposures Fossil Fuels

Performance

YTD
-38.01%
-38.01%
1 Month
+3.92%
+3.92%
3 Month
-25.61%
-25.61%
6 Month
+5.74%
+5.74%
1 Year
+45.21%
+45.21%

More News

Read More
Why Cracker Barrel Shares Are Trading Lower By Around 14%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Via Benzinga
Breaking Down Autolus Therapeutics: 4 Analysts Share Their Views
Via Benzinga
Autolus Therapeutics's Earnings Outlook
Via Benzinga
AUTL Stock Earnings: Autolus Therapeutics Misses EPS, Misses Revenue for Q1 2024
Via InvestorPlace
Despegar.com Posts Strong Sales, Joins Reddit, Robinhood And Other Big Stocks Moving Higher On Friday
Via Benzinga
Autolus Therapeutics Reports First Quarter 2024 Financial Results and Business Updates
From Autolus Therapeutics plc
Via GlobeNewswire
Autolus Therapeutics to Present Three Clinical Data Updates on obecabtagene autoleucel (obe-cel) in relapsed/refractory (r/r) B-Cell acute lymphoblastic leukemia (ALL) patients at the 2024 European Hematology Association (EHA) Congress
From Autolus Therapeutics plc
Via GlobeNewswire
Autolus Therapeutics Announces Delay to its First Quarter 2024 Earnings Release and Conference Call
From Autolus Therapeutics plc
Via GlobeNewswire
Abstract for longer-term follow-up and additional data analysis of Pivotal Phase 2 FELIX study of obe-cel for adult r/r B-ALL selected for an oral presentation at ASCO
From Autolus Therapeutics plc
Via GlobeNewswire
Autolus Therapeutics to Report First Quarter 2024 Financial Results and Host Conference Call on May 14, 2024
From Autolus Therapeutics plc
Via GlobeNewswire
12 Health Care Stocks Moving In Thursday's After-Market Session
Via Benzinga
Autolus Therapeutics announces acceptance of Marketing Authorization Application (MAA) by the European Medicines Agency (EMA) for obecabtagene autoleucel (obe-cel) for Patients with Relapsed/refractory (r/r) Adult B-Cell Acute Lymphoblastic Leukemia
From Autolus Therapeutics plc
Via GlobeNewswire
Autolus Therapeutics Announces Changes to its Board of Directors
From Autolus Therapeutics plc
Via GlobeNewswire
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Via Benzinga
12 Health Care Stocks Moving In Friday's After-Market Session
Via Benzinga
Autolus Therapeutics Reports Full Year 2023 Financial Results and Business Updates
From Autolus Therapeutics plc
Via GlobeNewswire
Autolus Therapeutics receives Medicines and Healthcare products Regulatory Agency (MHRA) certification for Nucleus commercial manufacturing site
From Autolus Therapeutics plc
Via GlobeNewswire
Earnings Scheduled For March 14, 2024
Via Benzinga
Autolus Therapeutics announces publication in Blood Cancer Journal
From Autolus Therapeutics plc
Via GlobeNewswire
Autolus Therapeutics to Report Full Year 2023 Financial Results and Business Updates on March 14, 2024
From Autolus Therapeutics plc
Via GlobeNewswire
Autolus Therapeutics announces publication in Nature Communications
From Autolus Therapeutics plc
Via GlobeNewswire
Autolus Announces Pricing of Underwritten Offering
From Autolus Therapeutics plc
Via GlobeNewswire
Autolus Therapeutics announces publication in ACS Chemical Biology
From Autolus Therapeutics plc
Via GlobeNewswire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.